Treatment-Free Survival After Nivolumab vs Pembrolizumab vs Nivolumab-Ipilimumab for Advanced Melanoma

IMPORTANCE: Treatment-free survival (TFS) represents an alternative time-to-event end point, accurately characterizing time spent free of systemic therapy, providing a more patient-centric view of immune checkpoint inhibitor (ICI) therapy regimens. There remains a lack of studies evaluating TFS outc...

Descripción completa

Detalles Bibliográficos
Autores principales: Gupta, Mehul, Stukalin, Igor, Meyers, Daniel, Goutam, Sid, Heng, Daniel Y. C., Cheng, Tina, Monzon, Jose, Navani, Vishal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2023
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10290253/
https://www.ncbi.nlm.nih.gov/pubmed/37351883
http://dx.doi.org/10.1001/jamanetworkopen.2023.19607

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10290253/
https://www.ncbi.nlm.nih.gov/pubmed/37351883
http://dx.doi.org/10.1001/jamanetworkopen.2023.19607

Ejemplares similares